Stock ADPT ADAPTIVE BIOTECHNOLOGIES CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Adaptive Biotechnologies Corporation

Equities

ADPT

US00650F1093

Market Closed - Nasdaq
Other stock markets
 21:00:00 08/05/2024 BST 		5-day change 1st Jan Change
3.18 USD +2.25% Intraday chart for Adaptive Biotechnologies Corporation +13.98% -35.10%
05-07 Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Reports Q1 Revenue $41.9M, vs. Street Est of $38.8M MT
05-07 Adaptive Biotechnologies Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Adaptive Biotechnologies: Q1 Earnings Snapshot
AQ
Adaptive Biotechnologies Reports First Quarter 2024 Financial Results
GL
Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
GL
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
GL
Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
GL
Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
AQ
Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
GL
Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
AQ
Adaptive Biotechnologies: Q4 Earnings Snapshot
AQ
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
GL
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
GL
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
AQ
Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GL
Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
AQ
Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
AQ
Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
GL
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting
GL
Adaptive Biotechnologies: Q3 Earnings Snapshot
AQ
Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update
GL
Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ADPT Stock
  4. News Adaptive Biotechnologies Corporation
  5. Press Releases